Chittorgarh.com Logo
Loading...

Advanced Enzyme Techno IPO review (Apply)

Review By Dilip Davda on Jul 14, 2016

Advanced Enzyme Technologies Ltd (AETL) is the largest Indian enzyme company, engaged in the research and development, manufacturing and marketing of 400+ proprietary products developed from 60 indigenous enzymes. Having more than two decades of fermentation experience in the production of enzymes, AETL ranks among the top 15 global companies in terms of enzyme sales, and have the second highest market share domestically, next only to the world’s largest enzyme company Novozymes.

The company operates in two primary business verticals namely Healthcare & Nutrition (human and animal) and Bio-Processing (food and non-food). By following critical industry trends, it focuses on ensuring that company’s enzyme products are relevant, helping customers to meet the evolving market demands.

AETL is a fully integrated enzyme manufacturing company driven by extensive focus on research and development (“R&D”) of various enzymes, enzyme blends, enzyme products and customized enzyme solutions. It strives to develop creative, cost-effective unique and innovative solutions, thereby enabling its customers to develop superior products and processes. The company has total six units out of which 4 are in India and 2 are in US. Similarly it has 4 R & D Centers out of which 3 are in India and 1 is in US. Its clientele includes names like Cipla, Sanofi, Alkem, Ipca, Emcure etc and has two third revenues from exports. Top 10 customers contribute 42% in top line. It serves more than 700 customers across 50 countries. Most of its products are tailor made and hence gives higher margins. Enzymes market is growing at a CAGR of 6% plus annually and trends are likely to continue.

To part finance its USA counterpart, the company is coming out with a fresh equity issue to the tune of Rs. 50 crore and an offer for sale of 4034470 equity shares by existing stakeholders for listing benefits. Thus the total offer size is around Rs. 405 to Rs. 411 crore based on lower and upper price bands. The company is issuing approximately 5.6 lakh fresh equity shares of Rs. 10 each. The issue is being made via book building route with a price band of Rs. 880-896. Minimum application is to be made for 16 shares and in multiples thereon, thereafter. Issue opens for subscription on 20.07.16 and will close on 22.07.16. Post allotment, shares will be listed on BSE and NSE.  BRLM to the issue are ICICI Securities Ltd and Axis Capital Ltd. Link Intime India Pvt Ltd is the registrar to the issue. 

Since inception in 1989 till March 1994 it issued equity shares at par. In December 1994 it issued further equity at a price of Rs. 50 per share, in March 1996 it issued equity at a price of Rs.30 per share and then again in November 2002 it issued equity in the price range of Rs. 26 and Rs. 50. In March 2007 it issued bonus in the ratio of 1 for and again in March 2010 in the same ratio. In July and November 2012 it issued equity at a price of Rs. 290 per share. Its current paid up equity capital of Rs. 21.77 cr. will stand enhanced to Rs. 22.33 cr. post this issue. 

On performance front, the company has (on consolidated basis) posted turnover of Rs. 220.42 cr, Rs. 239.45 cr. Rs. 223.11 cr. Rs. 293.76 cr. and net profit of Rs. 49.22 cr., Rs. 20.09 cr., Rs. 50.10 cr., Rs  78.44 cr. for FY 13, FY 14, FY 15 and FY 16 respectively. Thus is has posted CAGR of 14.4% for top lines and CAGR of 24.1% for bottom lines for these years despite troubled fiscal 2014.

If we attribute the last earnings on post IPO equity then the asking price is at a P/E of 25 plus. As per RHP there is no listed peer for this company to compare with and this is being the first mover IPO in enzymes which are specialty chemicals for healthcare. Thus one may compare it with pharma sector that commands composite P/E of around 32.

BRLMs to this offer have handled 21 IPOs in last three years out of which 6 IPOs closed below offer price on the debut day.

Conclusion: Being first mover IPO in the enzymes segment, it is catching fancy. Considering its track records and future prospects ahead, investors may consider investment for short to long term rewards.


Conclusion / Investment Strategy

Being first mover IPO in the enzymes segment, it is catching fancy. Considering its track records and future prospects ahead, investors may consider investment for short to long term rewards.

Reviewer recommends Subscribing to the issue.

Review By Dilip Davda on Jul 14, 2016

Review Author

DISCLAIMER: No financial information whatsoever published anywhere here should be construed as an offer to buy or sell securities, or as advice to do so in any way whatsoever. All matter published here is purely for educational and information purposes only and under no circumstances should be used for making investment decisions. Readers must consult a qualified financial advisor before making any actual investment decisions, based on information published here. Any reader taking decisions based on any information published here does so entirely at its own risk. Investors should bear in mind that any investment in stock markets is subject to unpredictable market-related risks. The above information is based on RHP and other documents available as of date coupled with market perception. The author has no plans to invest in this offer.

(SEBI registered Research Analyst-Mumbai).


About Dilip Davda

Dilip Davda, a freelance journalist

Dilip Davda is veteran journalist associated with stock market since 1978. He is contributing to print and electronic media on stock markets/insurance/finance since 1985.

Dilip Davda is a leading reviewer of public issues and NCDs in the primary stock market in India. The knowledge he gained over 3 decades while working in the stock market and a strong relationship with popular lead managers makes his reviews unique. His detail fundamental and financial analysis of companies coming up with IPO helps investors in the primary stock market. Dilip Davda has a special interest in analyzing the SME companies and writing reviews about their public issues. His reviews are regularly published online and in news papers.

Email: dilip_davda@rediffmail.com

Advanced Enzyme IPO FAQs

  1. 1. Why Advanced Enzyme IPO?

    The initial public offer (IPO) of Advanced Enzyme Technologies Ltd offers an early investment opportunity in Advanced Enzyme Technologies Ltd. A stock market investor can buy Advanced Enzyme IPO shares by applying in IPO before Advanced Enzyme Technologies Ltd shares get listed at the stock exchanges. An investor could invest in Advanced Enzyme IPO for short term listing gain or a long term.

  2. 2. How is Advanced Enzyme IPO?

    Read the Advanced Enzyme IPO recommendations by the leading analyst and leading stock brokers.

    • ABM Equity Research Ltd - Apply
    • Choice Equity Broking Pvt Ltd - Apply
    • Dilip Davda - Apply
    • GEPL Capital Ltd - Apply
    • Hem Securities - Apply
    • Way2Wealth Securities - Apply
  3. 3. Advanced Enzyme IPO what should investors do?

    Advanced Enzyme IPO offers an opportunity to buy IPO shares before they get listed at the stock exchanges. Read the Advanced Enzyme IPO Notes, Analysis and Recommendations by leading stock brokerage firms and experts in the above answer.

  4. 4. Is Advanced Enzyme IPO good?

    Our recommendation for Advanced Enzyme IPO is to subscribe.

  5. 5. Is Advanced Enzyme IPO worth Investing?

    As per the analysis by our lead analyst Mr. Dilip Davda, we suggest you to subscribe to the Advanced Enzyme IPO.

  6. 6. When will Advanced Enzyme IPO allotment status?

    The Advanced Enzyme IPO allotment status will be available on or around [.]. The allotted shares will be credited in demat account by [.]. Visit Advanced Enzyme IPO allotment status to check.

  7. 7. When will Advanced Enzyme IPO list?

    The Advanced Enzyme IPO will list on Monday, August 1, 2016, at BSE, NSE.